argenx (ARGX) Q4 2025 earnings summary

Executive summary

• Achieved $4.2 billion in full-year 2025 global product net sales, up 90% year-over-year, and $1.3 billion in Q4 sales, treating 19,000 patients globally and launching a prefilled syringe for self-injection, driving strong adoption and growth across all regions and indications.

• Marked first year of operating profitability with $1.1 billion in operating income for 2025, supported by robust VYVGART adoption and label expansion opportunities in MG and CIDP.

• Positive Phase 3 ADAPT-OCULUS results in ocular myasthenia gravis (OMG/MG) and progress in seronegative MG position the lead product for the broadest MG label in the U.S.

• Continued expansion into CIDP, autoimmune myositis, Sjögren's disease, and MMN, with a robust late-stage pipeline and next-generation FcRn assets.

• Leadership transition announced, with Karen Massey taking over as CEO to drive the next phase of growth.

Financial highlights

• Q4 2025 product net sales reached $1.3 billion; full-year net sales were $4.2 billion, representing 90% year-over-year growth.

• U.S. Q4 product revenue was $1.1 billion, up 68% from the prior year; Japan contributed $63 million, rest of world $110 million, and China $26 million.

• Operating profit for Q4 was $367 million and $1.1 billion for the year, marking the first year of annual operating profitability.

• Net profit for FY 2025 was $1.29 billion, up from $833 million in 2024.

• Cash and equivalents at year-end totaled $4.4 billion, up over $1 billion year-over-year.

Outlook and guidance

• Operating expenses expected to grow at a similar percentage in 2026, with most growth in R&D to support pipeline advancement.

• Revenue growth anticipated to outpace OpEx growth, supporting increasing operating margins and long-term profitability.

• Label expansions in seronegative and ocular MG expected to add 18,000 addressable patients; pricing for new indications expected to be similar to current MG pricing ($225,000 net per patient).

• Vision 2030 targets 50,000 patients on treatment, 10 labeled indications, and 5 new molecules in Phase 3 by 2025.

• Six registrational readouts expected over the next 24 months, including key Phase 3 data for multiple indications.